Skip to main content
SpringerLink
Log in

Current Ebola Virus Vaccine Progress

  • Leading Article
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–9.

    Article  CAS  PubMed  Google Scholar 

  2. Mire CE, Geisbert TW, Feldmann H, Marzi A. Ebola virus vaccines—reality or fiction? Expert Rev Vacc. 2016;15:1421–30.

    Article  CAS  Google Scholar 

  3. Marzi A, Robertson SJ, Haddock E, EBOLA VACCINE, et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–42.

    Article  CAS  PubMed  Google Scholar 

  4. Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–13.

    Article  CAS  PubMed  Google Scholar 

  5. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vacc Immunol CVI. 2006;13:1267–77.

    Article  CAS  Google Scholar 

  6. Branswell H. As foreign powers approve Ebola vaccines, U.S. drug makers lag in development pipeline. https://www.statnews.com/2017/12/08/ebola-vaccine-development/.

  7. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 923–56.

    Google Scholar 

  8. WHO. Ebola situation report, 30 March 2016. Geneva: World Health Organization; 2016.

    Google Scholar 

  9. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393–400.

    Article  CAS  PubMed  Google Scholar 

  10. Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385:2272–9.

    Article  CAS  PubMed  Google Scholar 

  11. Li JX, Hou LH, Meng FY, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324–34.

    Article  PubMed  Google Scholar 

  12. Wu L, Zhang Z, Gao H, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vacc Immunother. 2017;13:2078–85.

    Article  Google Scholar 

  13. Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389:621–8.

    Article  CAS  PubMed  Google Scholar 

  14. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. 2016;374:1647–60.

    Article  CAS  PubMed  Google Scholar 

  15. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report. N Engl J Med. 2017;376:330–41.

    Article  CAS  PubMed  Google Scholar 

  16. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66.

    Article  CAS  PubMed  Google Scholar 

  17. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215:1789–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. ElSherif MS, Brown C, MacKinnon-Cameron D, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017;189:E819–27.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Heppner DG Jr, Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17:854–66.

    Article  CAS  PubMed  Google Scholar 

  22. Agnandji ST, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial. PLoS Med. 2017;14:e1002402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vacc Immunother. 2017;13:613–20.

    Article  CAS  Google Scholar 

  25. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med. 2015;373:775–6.

    Article  Google Scholar 

  26. Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311–20.

    Article  CAS  PubMed  Google Scholar 

  28. Ewer K, Rampling T, Venkatraman N, et al. A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374:1635–46.

    Article  CAS  PubMed  Google Scholar 

  29. Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA J Am Med Assoc. 2016;315:1610–23.

    Article  CAS  Google Scholar 

  30. Winslow RL, Milligan ID, Voysey M, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. JAMA J Am Med Assoc. 2017;317:1075–7.

    Article  Google Scholar 

  31. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017—conclusions and recommendations. Wkly Epidemiol Rec. 2017;92:301–20.

    Google Scholar 

  32. Centers for Disease Control and Prevention. 2018 Eastern Democratic Republic of the Congo. https://www.cdc.gov/vhf/ebola/outbreaks/drc/2018-august.html.

  33. Medcins sans Frontieres. DRC 2018 Ebola outbreaks—Crisis update November 2018. https://www.msf.org/drc-2018-ebola-outbreak-crisis-update.

  34. World Health Organization. Ebola virus disease—Democratic Republic of the Congo. http://www.who.int/csr/don/14-september-2018-ebola-drc/en/.

  35. World Health Organization. Ebola situation report, 13 November 2018. Geneva: World Health Organization; 2018.

    Google Scholar 

  36. Hackett DW. Uganda prepares it’s Ebola defense. https://www.precisionvaccinations.com/merck-rvsv-ebola-vaccine-candidate-successfully-given-more-16000-volunteers-africa.

  37. Huttner A, Agnandji ST, Combescure C, et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018;18:738–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Huttner A, Siegrist CA. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? Expert Rev Vacc. 2018;17:1105–10.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Heinz Feldmann for his critical review of the manuscript.

Author information

Authors and Affiliations

  1. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MO, USA

    Andrea Marzi

  2. Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA

    Chad E. Mire

Authors
  1. Andrea Marzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chad E. Mire
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chad E. Mire.

Ethics declarations

Funding

This article was funded by the Division of Intramural Research, NIAID, NIH and UC7 AI094660 to UTMB for BSL-4 operations.

Conflict of interest

Andrea Marzi and Chad Mire have no conflicts of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marzi, A., Mire, C.E. Current Ebola Virus Vaccine Progress. BioDrugs 33, 9–14 (2019). https://doi.org/10.1007/s40259-018-0329-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-018-0329-7

Search

Navigation